Status:
COMPLETED
Decatecholaminisation of Septic Shock With Dexmedetomidine and In-hospital Mortality
Lead Sponsor:
Mansoura University
Conditions:
Septic Shock
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study aims to determine whether the infusion of DEX in septic shock can reduce in-hospital mortality, norepinephrine infusion, need and duration for mechanical ventilation, and acute kidney injury...
Detailed Description
During septic shock, acute stress response includes neural and humoral autonomic flaring, which tend to be beneficial in the short term. Once shock occurs, it is a failure of the compensation trial. I...
Eligibility Criteria
Inclusion
- Adult (≥ 18 years) patients of either sex who develop septic shock with heart rate (HR) \> 90 beats per minute (bpm).
- We choose the definition of septic shock as the start of norepinephrine (NE) infusion to maintain the mean arterial blood pressure (MAP) of ≥ 65 mmHg in a case of sepsis (≥ 2 SIRS criteria plus suspicion or confirmation of infection).
Exclusion
- Patient refusal or inability to obtain consent
- Failure of hemodynamic stabilization or hemoglobin \< 7 gm/dl at time of inclusion
- Severe cardiac dysfunction (Ejection Fraction (EF) \< 30%)
- History of heart block or patient on pacemaker
- Chronic liver Disease (Child-Pugh classification C)
- Severe valvular heart disease
- Pregnancy
Key Trial Info
Start Date :
March 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2023
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT05283083
Start Date
March 25 2022
End Date
March 1 2023
Last Update
May 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospitals
Al Mansurah, Aldakahlia, Egypt, 35516